[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575146":3},{"organization":4,"outcomesModule":7,"designInfo":79,"detailedDescription":78,"studyPopulation":78,"armGroups":85,"interventions":111,"overallOfficials":129,"centralContacts":133,"locations":139,"responsibleParty":298,"collaborators":78,"id":300,"slug":301,"hasResults":302,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":78,"eligibilityCriteria":306,"healthyVolunteers":302,"sex":307,"minAge":308,"maxAge":78,"enrollmentInfo":309,"targetDuration":78,"studyType":312,"phases":313,"briefSummary":315,"conditions":316,"keywords":78,"overallStatus":142,"whyStopped":78,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":329},{"fullName":5,"class":6},"Janssen Research & Development, LLC","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":20,"otherOutcomes":78},[9,13,17],{"measure":10,"description":11,"timeFrame":12},"Part 1: Number of Participants with Dose-limiting Toxicity (DLT)","DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.","Up to 28 days",{"measure":14,"description":15,"timeFrame":16},"Number of Participants with Adverse Events (AEs) by Severity","An AE is any untoward medical occurrence in a clinical study participant that does not necessarily have a causal relationship with the pharmaceutical\u002Fbiological agent under study. Severity will be graded according to the national cancer institute common terminology criteria for adverse events (NCI-CTCAE) version 5.0. Severity scale ranges from grade 1 (mild) to grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse event.","Up to 3 Years and 3 months",{"measure":18,"description":19,"timeFrame":16},"Number of Participants with Clinically Significant Laboratory Abnormalities","Participants with clinically significant laboratory abnormalities (hematology and chemistry) will be reported.",[21,24,27,30,33,36,39,42,45,48,51,54,57,60,63,66,69,72,75],{"measure":22,"description":23,"timeFrame":16},"Percentage of Participants With Overall Response Rate","Overall response rate is defined as percentage of participants with newly diagnosed multiple myeloma (NDMM), relapsed or refractory multiple myeloma (R\u002FR MM), or high-risk smoldering multiple myeloma (SMM) who have a partial response (PR) or better evaluated by the investigator as per international myeloma working group (IMWG) 2016 criteria.",{"measure":25,"description":26,"timeFrame":16},"Percentage of Participants With Very Good Partial Response (VGPR) or Better Response Rate","VGPR or better response rate is defined as the percentage of participants with NDMM, R\u002FR MM, or high-risk SMM who achieve a VGPR or better response (stringent complete response \\[sCR\\]+ complete response \\[CR\\]+VGPR) according to the IMWG 2016 criteria.",{"measure":28,"description":29,"timeFrame":16},"Percentage of Participants With CR or Better Response Rate","CR or better response rate is defined as the percentage of participants with NDMM R\u002FR MM, or high-risk SMM who achieve a CR or better response (sCR+CR) according to the IMWG 2016 criteria.",{"measure":31,"description":32,"timeFrame":16},"Percentage of Participants With sCR or Better Response Rate","sCR rate is defined as the percentage of participants with NDMM R\u002FR MM, or high-risk SMM who achieve an sCR according to the IMWG 2016 criteria.",{"measure":34,"description":35,"timeFrame":16},"Duration of Response (DOR)","DOR is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of progressive disease (PD), as per IMWG 2016 response criteria, or death due to progression, whichever occurs first in participants with NDMM, R\u002FR MM, or high-risk SMM.",{"measure":37,"description":38,"timeFrame":16},"Time to Response (TTR)","TTR is defined as the time between date of first dose of study treatment and the first efficacy evaluation at which the participants with NDMM, R\u002FR MM, or high-risk SMM has met all criteria for PR or better as defined by IMWG 2016 response criteria.",{"measure":40,"description":41,"timeFrame":16},"Percentage of Participants With Hematologic Response As Defined by International Amyloidosis Consensus Criteria","Hematologic response is defined as percentage of participants with newly diagnosed amyloid light chain (ND AL) amyloidosis who achieve complete response, very good partial response, partial response, no response and progression as defined by International amyloidosis consensus criteria present in the protocol will be reported.",{"measure":43,"description":44,"timeFrame":16},"DOR as Defined by International Amyloidosis Consensus Criteria","DOR is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of progressive disease (PD), as per International amyloidosis consensus criteria, or death due to progression, whichever occurs first in participants with ND AL amyloidosis.",{"measure":46,"description":47,"timeFrame":16},"TTR as Defined by International Amyloidosis Consensus Criteria","TTR is defined as the time between date of first dose of study treatment and the first efficacy evaluation at which the participant with ND AL amyloidosis has met all criteria for PR or better as defined by International amyloidosis consensus criteria.",{"measure":49,"description":50,"timeFrame":16},"Serum Concentration of JNJ-79635322 and Daratumumab","Serum samples will be analyzed to determine concentrations of JNJ-79635322 and daratumumab.",{"measure":52,"description":53,"timeFrame":16},"Area Under the Serum Concentration Time Curve from Time Zero to Infinity (AUCinf) for JNJ-79635322 and Daratumumab","AUCinf for JNJ-79635322 and daratumumab will be reported.",{"measure":55,"description":56,"timeFrame":16},"Area Under the Serum Concentration Time Curve from Time Zero to the Last Measurable Concentration [AUC(0-t)] for JNJ-79635322 and Daratumumab","AUC(0-t) for JNJ-79635322 and daratumumab will be reported.",{"measure":58,"description":59,"timeFrame":16},"Area Under the Serum Concentration Time Curve During the Dosing Interval (AUCtau) for JNJ-79635322 and Daratumumab","AUCtau for JNJ-79635322 and daratumumab will be reported.",{"measure":61,"description":62,"timeFrame":16},"Maximum Serum Concentration (Cmax) for JNJ-79635322 and Daratumumab","Cmax for JNJ-79635322 and daratumumab will be reported.",{"measure":64,"description":65,"timeFrame":16},"Half Life (T1\u002F2) for JNJ-79635322 and Daratumumab","T1\u002F2 for JNJ-79635322 and daratumumab will be reported.",{"measure":67,"description":68,"timeFrame":16},"Time to Reach Cmax (Tmax) for JNJ-79635322 and Daratumumab","Tmax for JNJ-79635322 and daratumumab will be reported.",{"measure":70,"description":71,"timeFrame":16},"Systemic Clearance (CL\u002FF) for JNJ-79635322 and Daratumumab","CL\u002FF for JNJ-79635322 and daratumumab will be reported.",{"measure":73,"description":74,"timeFrame":16},"Apparent Volume of Distribution at Steady State (Vss\u002FF) for JNJ-79635322 and Daratumumab","Vss\u002FF for JNJ-79635322 and daratumumab will be reported.",{"measure":76,"description":77,"timeFrame":16},"Number of Participants with Presence of Anti-Drug Antibodies to JNJ-79635322 and Daratumumab","Participants with anti-drug antibodies to JNJ-79635322 and daratumumab will be reported.",null,{"allocation":80,"interventionModel":81,"interventionModelDescription":78,"primaryPurpose":82,"observationalModel":78,"timePerspective":78,"maskingInfo":83},"NON_RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":84,"maskingDescription":78,"whoMasked":78},"NONE",[86,93,98,103,107],{"label":87,"type":88,"description":89,"interventionNames":90},"Treatment Regimen A and C: JNJ-79635322+Daratumumab","EXPERIMENTAL","Participants who have received 1-3 prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) (Treatment regimen A1 and A3) will receive JNJ-79635322 along with daratumumab to establish the recommended phase 2 doses (RP2D\\[s\\]) of the JNJ-79635322 during Part 1 (Dose Escalation) of the study. Based on the study evaluation team (SET) decision, enrollment may proceed in participants with newly diagnosed multiple myeloma (NDMM) (Treatment regimens A2, A4 and C). Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of JNJ-79635322 combination treatment regimen(s) at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens.",[91,92],"Drug: JNJ-79635322","Drug: Daratumumab",{"label":94,"type":88,"description":95,"interventionNames":96},"Treatment Regimen B: JNJ-79635322+Pomalidomide","Participants who have received greater than or equal to (\\>=)1 prior line of therapy, including a PI and lenalidomide, and are lenalidomide refractory or \\>=2 prior lines of therapy, including a PI and lenalidomide will receive JNJ-79635322 along with pomalidomide to establish the RP2D(s) of the JNJ-79635322 during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of JNJ-79635322 combination treatment regimen(s) at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens.",[91,97],"Drug: Pomalidomide",{"label":99,"type":88,"description":100,"interventionNames":101},"Treatment Regimen D and E: JNJ-79635322 + Daratumumab + Lenalidomide Combination","Participants with NDMM will receive JNJ-79635322 along with daratumumab and lenalidomide to establish the RP2D\\[s\\] of the JNJ-79635322 during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of JNJ-79635322 combination treatment regimen(s) at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens.",[91,92,102],"Drug: Lenalidomide",{"label":104,"type":88,"description":105,"interventionNames":106},"Treatment Regimen F: JNJ-79635322 + Daratumumab","Participants with newly diagnosed amyloid light chain (ND AL) amyloidosis will receive JNJ-79635322 in treatment regimen F along with daratumumab to establish the RP2D\\[s\\] of the JNJ-79635322 during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of JNJ-79635322 and daratumumab at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens.",[91,92],{"label":108,"type":88,"description":109,"interventionNames":110},"Treatment Regimen G: JNJ-79635322 + Daratumumab","Participants with high-risk smoldering multiple myeloma (SMM) will receive JNJ-79635322 in treatment regimen G along with daratumumab to establish the RP2D\\[s\\] of the JNJ-79635322 during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of JNJ-79635322 and daratumumab at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens.",[91,92],[112,117,121,125],{"type":113,"name":114,"description":115,"armGroupLabels":116,"otherNames":78},"DRUG","JNJ-79635322","JNJ-79635322 will be administered subcutaneously.",[87,94,99,104,108],{"type":113,"name":118,"description":119,"armGroupLabels":120,"otherNames":78},"Daratumumab","Daratumumab will be administered subcutaneously.",[87,99,104,108],{"type":113,"name":122,"description":123,"armGroupLabels":124,"otherNames":78},"Pomalidomide","Pomalidomide will be administered orally.",[94],{"type":113,"name":126,"description":127,"armGroupLabels":128,"otherNames":78},"Lenalidomide","Lenalidomide will be administered orally.",[99],[130],{"name":131,"affiliation":5,"role":132},"Janssen Research & Development, LLC Clinical Trial","STUDY_DIRECTOR",[134],{"name":135,"role":136,"phone":137,"phoneExt":78,"email":138},"Study Contact","CONTACT","844-434-4210","Participate-In-This-Study1@its.jnj.com",[140,154,164,175,184,193,202,211,222,231,240,249,260,269,278,289],{"facility":141,"status":142,"city":143,"state":144,"zip":145,"country":146,"countryCode":147,"cosmosGeoPoint":148,"geoPoint":153,"contacts":78},"Colorado Blood Cancer Institute","RECRUITING","Denver","Colorado","80218","United States","US",{"type":149,"coordinates":150},"Point",[151,152],-104.9847,39.73915,{"lat":152,"lon":151},{"facility":155,"status":142,"city":156,"state":157,"zip":158,"country":146,"countryCode":147,"cosmosGeoPoint":159,"geoPoint":163,"contacts":78},"Winship Cancer Institute Emory University","Atlanta","Georgia","30322",{"type":149,"coordinates":160},[161,162],-84.38798,33.749,{"lat":162,"lon":161},{"facility":165,"status":142,"city":166,"state":78,"zip":167,"country":168,"countryCode":169,"cosmosGeoPoint":170,"geoPoint":174,"contacts":78},"Monash Medical Centre","Clayton","3168","Australia","AU",{"type":149,"coordinates":171},[172,173],145.11667,-37.91667,{"lat":173,"lon":172},{"facility":176,"status":142,"city":177,"state":78,"zip":178,"country":168,"countryCode":169,"cosmosGeoPoint":179,"geoPoint":183,"contacts":78},"St Vincents Hospital Melbourne","Fitzroy","3065",{"type":149,"coordinates":180},[181,182],144.97833,-37.79839,{"lat":182,"lon":181},{"facility":185,"status":142,"city":186,"state":78,"zip":187,"country":168,"countryCode":169,"cosmosGeoPoint":188,"geoPoint":192,"contacts":78},"Peter MacCallum Cancer Centre","Melbourne","3000",{"type":149,"coordinates":189},[190,191],144.96332,-37.814,{"lat":191,"lon":190},{"facility":194,"status":142,"city":195,"state":78,"zip":196,"country":168,"countryCode":169,"cosmosGeoPoint":197,"geoPoint":201,"contacts":78},"Calvary Mater Newcastle Hospital","Waratah","2298",{"type":149,"coordinates":198},[199,200],151.72647,-32.90667,{"lat":200,"lon":199},{"facility":203,"status":142,"city":204,"state":78,"zip":205,"country":168,"countryCode":169,"cosmosGeoPoint":206,"geoPoint":210,"contacts":78},"Wollongong Hospital","Wollongong","2500",{"type":149,"coordinates":207},[208,209],150.89345,-34.424,{"lat":209,"lon":208},{"facility":212,"status":142,"city":213,"state":78,"zip":214,"country":215,"countryCode":216,"cosmosGeoPoint":217,"geoPoint":221,"contacts":78},"Carmel Medical Center","Haifa","3436212","Israel","IL",{"type":149,"coordinates":218},[219,220],34.99928,32.81303,{"lat":220,"lon":219},{"facility":223,"status":142,"city":224,"state":78,"zip":225,"country":215,"countryCode":216,"cosmosGeoPoint":226,"geoPoint":230,"contacts":78},"Hadassah Medical Center","Jerusalem","9112001",{"type":149,"coordinates":227},[228,229],35.21633,31.76904,{"lat":229,"lon":228},{"facility":232,"status":142,"city":233,"state":78,"zip":234,"country":215,"countryCode":216,"cosmosGeoPoint":235,"geoPoint":239,"contacts":78},"Sheba Medical Center","Ramat Gan","52621",{"type":149,"coordinates":236},[237,238],34.81065,32.08227,{"lat":238,"lon":237},{"facility":241,"status":142,"city":242,"state":78,"zip":243,"country":215,"countryCode":216,"cosmosGeoPoint":244,"geoPoint":248,"contacts":78},"Tel Aviv Sourasky Medical Center","Tel Aviv","64239",{"type":149,"coordinates":245},[246,247],34.78057,32.08088,{"lat":247,"lon":246},{"facility":250,"status":142,"city":251,"state":78,"zip":252,"country":253,"countryCode":254,"cosmosGeoPoint":255,"geoPoint":259,"contacts":78},"VU Medisch Centrum","Amsterdam","1081 HV","Netherlands","NL",{"type":149,"coordinates":256},[257,258],4.88969,52.37403,{"lat":258,"lon":257},{"facility":261,"status":142,"city":262,"state":78,"zip":263,"country":253,"countryCode":254,"cosmosGeoPoint":264,"geoPoint":268,"contacts":78},"Universitair Medisch Centrum Groningen","Groningen","9713 GZ",{"type":149,"coordinates":265},[266,267],6.56667,53.21917,{"lat":267,"lon":266},{"facility":270,"status":142,"city":271,"state":78,"zip":272,"country":253,"countryCode":254,"cosmosGeoPoint":273,"geoPoint":277,"contacts":78},"UMC Utrecht","Utrecht","3584 CX",{"type":149,"coordinates":274},[275,276],5.12222,52.09083,{"lat":276,"lon":275},{"facility":279,"status":142,"city":280,"state":78,"zip":281,"country":282,"countryCode":283,"cosmosGeoPoint":284,"geoPoint":288,"contacts":78},"Hosp. Clinic de Barcelona","Barcelona","08036","Spain","ES",{"type":149,"coordinates":285},[286,287],2.15899,41.38879,{"lat":287,"lon":286},{"facility":290,"status":142,"city":291,"state":78,"zip":292,"country":282,"countryCode":283,"cosmosGeoPoint":293,"geoPoint":297,"contacts":78},"Hosp Clinico Univ de Salamanca","Salamanca","37007",{"type":149,"coordinates":294},[295,296],-5.66388,40.96882,{"lat":296,"lon":295},{"type":299,"investigatorFullName":78,"investigatorTitle":78,"investigatorAffiliation":78,"oldNameTitle":78,"oldOrganization":78},"SPONSOR","100575146","phase-1-a-study-of-jnj-79635322-in-combination-with-daratumumab-with-or-without-lenalidomide-or-in-combination-with-pomalidomide-for-multiple-myeloma-100575146",false,"NCT06768489","A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma","A Phase 1b Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or in Combination With Pomalidomide for Multiple Myeloma","Inclusion Criteria for newly diagnosed multiple myeloma (NDMM) and relapsed or refractory multiple myeloma (R\u002FR MM):\n\n* Have documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria\n* Meet treatment regimen-specific requirements as follows: Treatment regimen A (JNJ-79635322+daratumumab):Treatment regimens A1 and A3: Have been treated with 1 to 3 prior lines of therapy, including a proteasome inhibitor (PI) and an inhibitor, immunomodulatory drug (IMiD) therapy for the treatment of multiple myeloma (MM); Treatment regimens A2 and A4: Newly diagnosed MM naïve to multiple myeloma (or other related plasma cell neoplasm)-directed treatments; Treatment regimen B (JNJ-79635322+pomalidomide): Have received greater than or equal to (\\>=) 1 prior line of therapy, including a PI and lenalidomide, and are lenalidomide refractory OR \\>=2 prior lines of therapy, including a PI and lenalidomide; Treatment Regimens C, D, and E: Newly diagnosed MM naïve to multiple myeloma (or other related plasma cell neoplasm)-directed treatments\n* Have a weight \\>=40 kilograms\n* Must have an Eastern Cooperative Oncology Group status of 0 or 2\n* Have measurable disease at screening as defined by at least 1 of the following: a) Serum monoclonal protein (M-protein) level \\>= 0.5 gram per deciliter (g\u002FdL); or b) Urine M-protein level \\>=200 milligram (mg)\u002F24 hours; or c) Light chain multiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) \\>= 10 mg\u002FdL and abnormal serum Ig kappa lambda FLC ratio. d) For participants without measurable disease in the serum, urine, or involved FLC: presence of 1 or more focus of extramedullary disease which meets the following criteria: extramedullary plasmacytoma not contiguous with a bone lesion, at least 1 lesion \\>=2 centimeter (cm) (at its greatest dimension) diameter on whole body positron emission tomography-computed tomography (or whole-body magnetic resonance imaging approved by sponsor), and not previously radiated\n\nInclusion criteria for newly diagnosed amyloid light chain (ND AL) Amyloidosis\n\n* Have a histopathological diagnosis of amyloidosis\n* Have an ECOG performance status of 0 to 1\n\nInclusion criteria for High-risk smoldering multiple myeloma (SMM)\n\n* Have a diagnosis of SMM (per IMWG criteria) for less than or equal to (\\\u003C=) 5 years with measurable disease at the time of enrollment as defined in the protocol\n* Have an ECOG performance status of 0 to 1\n\nExclusion Criteria for NDMM and R\u002FR MM:\n\n* Prior antitumor therapy as follows, in the specified time frame prior to the first dose of study treatment: a) Targeted therapy, epigenetic therapy, monoclonal antibody (mAb) treatment, or treatment with an investigational drug or an invasive investigational medical device within 21 days or 5 half-lives, whichever is less. b) Gene-modified adoptive cell therapy (example, chimeric antigen receptor \\[CAR\\] modified T cells, natural killer cells) within 90 days. c) Prior anti-CD38 directed therapy within 90 days (for treatment regimens A, C, D and E only; within 21 days for treatment regimen B). d) Conventional chemotherapy within 21 days. e) PI therapy within 14 days. f) Immunomodulatory agent therapy within 7 days. g) Radiotherapy within 14 days\n* Stem cell transplantation: a) Allogeneic stem cell transplant within 6 months before the first dose of study treatment. b) Received an autologous stem cell transplant \\\u003C=12 weeks before the first dose of study treatment\n* Nonhematologic toxicity from prior anticancer therapy that has not resolved to baseline level or to grade \\\u003C=1 (except alopecia, tissue post-RT fibrosis \\[any grade\\] or peripheral neuropathy grade \\\u003C=3)\n* Prior treatment with CD3-redirecting therapy\n\nExclusion Criteria for ND AL Amyloidosis\n\n* Previous or current diagnosis of symptomatic multiple myeloma, including the presence of lytic bone disease, plasmacytomas, \\>=60 percent (%) plasma cells in the bone marrow, or hypercalcemia\n* Macroglossia that impairs swallowing difficulty\n* Prior therapy for AL amyloidosis or multiple myeloma\n\nExclusion Criteria for High-risk SMM\n\n* Multiple myeloma, requiring treatment\n* Primary systemic AL (immunoglobulin light chain) amyloidosis\n\nExclusion criteria for all participants:\n\n* Any serious underlying medical conditions, such as: Evidence of active viral, bacterial, or systemic fungal infection requiring ongoing antiviral, antibacterial, or antifungal treatment; active autoimmune disease requiring systemic immunosuppressive therapy within 6 months before start of study treatment; cardiovascular dysfunction; pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation; human immunodeficiency (HIV) infection; active hepatitis B or C infection; stroke or seizure within 6 months prior to first dose of study treatment\n* Known or suspected chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) less than (\\\u003C) 50 percent (%)","ALL","18 Years",{"count":310,"type":311},276,"ESTIMATED","INTERVENTIONAL",[314],"PHASE1","The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses \\[RP2Ds\\]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or without lenalidomide or with pomalidomide; and for Part 2 (Dose Expansion) is to further characterize the safety and tolerability of JNJ-79635322 combination treatment regimens at selected RP2D(s).",[317,318,319],"Multiple Myeloma","Smoldering Multiple Myeloma","Immunoglobulin Light-chain Amyloidosis","2026-09-24",{"date":322,"type":323},"2026-09-25","ACTUAL",{"date":325,"type":323},"2024-12-04",{"date":327,"type":311},"2029-06-29",{"name":5,"class":6},16]